Abeona Therapeutics acquires EoE drug candidate from Ellodi for $20 million in stock
ABEO•Abeona Therapeutics acquired the eosinophilic esophagitis candidate APT-1011, renamed ABO-801, from Ellodi Pharmaceuticals for $20 million in stock, with no upfront cash. Ellodi may also receive up to $60 million in approval and sales milestones, plus low-to-mid-teens royalties on net sales.
1. Deal terms
Abeona Therapeutics acquired APT-1011, renamed ABO-801, from Ellodi Pharmaceuticals for $20 million in common stock and no upfront cash. Ellodi is eligible for $30 million upon FDA approval, up to $30 million in sales milestones, and low-to-mid-teens royalties on net sales.
2. Trial results and plans
ABO-801 is a once-daily oral therapy candidate for eosinophilic esophagitis with FDA Orphan Drug and Fast Track designations. Neither of two completed Phase 3 studies met its prespecified co-primary patient-reported symptom endpoint, though both showed statistically significant improvements in several endoscopic measures. A planned Phase 3 study is expected to begin in mid-2027, with topline results anticipated by the end of 2028, subject to initiation and enrollment.
